Intersect ENT (XENT) Stock Pops on First Trading Day After IPO

NEW YORK (TheStreet) -- Intersect ENT  (XENT) surged more than 18% Thursday, its first day of trading after its IPO.

The biotech company, which manufactures drug delivery devices used by Ear, Nose and Throat doctors, priced its initial public offering of 5 million shares at $11 a share, the low end of the expected $11 to $13 range. The offering, which the company expects to close on or around July 29, includes a 30-day option for underwriters to purchase up to an additional 750,000 shares.

The stock opened at $13.20 and hit a high of $13.65 as of 12:57 p.m., by which point more than 2.6 million shares had changed hands.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

XENT Price Chart XENT Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%